These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 25243616)

  • 41. Progress and prospects for targeting Hsp90 to treat fungal infections.
    Veri A; Cowen LE
    Parasitology; 2014 Aug; 141(9):1127-37. PubMed ID: 24560124
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens.
    Cowen LE
    Curr Opin Microbiol; 2013 Aug; 16(4):377-84. PubMed ID: 23588026
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphoproteomics of Aspergillus fumigatus Exposed to the Antifungal Drug Caspofungin.
    Mattos EC; Palmisano G; Goldman GH
    mSphere; 2020 May; 5(3):. PubMed ID: 32461274
    [No Abstract]   [Full Text] [Related]  

  • 44. A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi.
    Dos Reis TF; de Castro PA; Bastos RW; Pinzan CF; Souza PFN; Ackloo S; Hossain MA; Drewry DH; Alkhazraji S; Ibrahim AS; Jo H; Lightfoot JD; Adams EM; Fuller KK; deGrado WF; Goldman GH
    Nat Commun; 2023 Apr; 14(1):2052. PubMed ID: 37045836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brilacidin, a host defense peptide mimetic, potentiates ibrexafungerp antifungal activity against the human pathogenic fungus
    Dos Reis TF; Diehl C; Pinzan CF; de Castro PA; Goldman GH
    Microbiol Spectr; 2024 Aug; 12(8):e0088824. PubMed ID: 38980033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
    Steinbach WJ; Singh N; Miller JL; Benjamin DK; Schell WA; Heitman J; Perfect JR
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4922-5. PubMed ID: 15561883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Caspofungin exposure alters the core septin AspB interactome of Aspergillus fumigatus.
    Vargas-Muñiz JM; Renshaw H; Waitt G; Soderblom EJ; Moseley MA; Palmer JM; Juvvadi PR; Keller NP; Steinbach WJ
    Biochem Biophys Res Commun; 2017 Apr; 485(2):221-226. PubMed ID: 28238781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Newer combination antifungal therapies for invasive aspergillosis.
    Steinbach WJ; Juvvadi PR; Fortwendel JR; Rogg LE
    Med Mycol; 2011 Apr; 49 Suppl 1(0 1):S77-81. PubMed ID: 20608784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms.
    Chowdhary A; Sharma C; Hagen F; Meis JF
    Future Microbiol; 2014; 9(5):697-711. PubMed ID: 24957095
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.
    Falloon K; Juvvadi PR; Richards AD; Vargas-Muñiz JM; Renshaw H; Steinbach WJ
    PLoS One; 2015; 10(9):e0137869. PubMed ID: 26366742
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Azole resistant Aspergillus fumigatus: an emerging problem.
    Lelièvre L; Groh M; Angebault C; Maherault AC; Didier E; Bougnoux ME
    Med Mal Infect; 2013 Apr; 43(4):139-45. PubMed ID: 23562488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MOB-mediated regulation of septation initiation network (SIN) signaling is required for echinocandin-induced hyperseptation in
    Thorn HI; Guruceaga X; Martin-Vicente A; Nywening AV; Xie J; Ge W; Fortwendel JR
    mSphere; 2024 Mar; 9(3):e0069523. PubMed ID: 38349166
    [No Abstract]   [Full Text] [Related]  

  • 53. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy.
    Amorim A; Guedes-Vaz L; Araujo R
    Int J Antimicrob Agents; 2010 Apr; 35(4):396-9. PubMed ID: 20138740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aspergillus species intrinsically resistant to antifungal agents.
    Van Der Linden JW; Warris A; Verweij PE
    Med Mycol; 2011 Apr; 49 Suppl 1():S82-9. PubMed ID: 20662634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elucidating drug resistance in human fungal pathogens.
    Xie JL; Polvi EJ; Shekhar-Guturja T; Cowen LE
    Future Microbiol; 2014; 9(4):523-42. PubMed ID: 24810351
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Membrane and cell wall targets in Aspergillus fumigatus.
    Beauvais A; Latgé JP
    Drug Resist Updat; 2001 Feb; 4(1):38-49. PubMed ID: 11512152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antifungal activity of Myriocin on clinically relevant Aspergillus fumigatus strains producing biofilm.
    Perdoni F; Signorelli P; Cirasola D; Caretti A; Galimberti V; Biggiogera M; Gasco P; Musicanti C; Morace G; Borghi E
    BMC Microbiol; 2015 Oct; 15():248. PubMed ID: 26519193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
    Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms.
    Mowat E; Lang S; Williams C; McCulloch E; Jones B; Ramage G
    J Antimicrob Chemother; 2008 Dec; 62(6):1281-4. PubMed ID: 18819968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aspergillus fumigatus biofilms: Toward understanding how growth as a multicellular network increases antifungal resistance and disease progression.
    Morelli KA; Kerkaert JD; Cramer RA
    PLoS Pathog; 2021 Aug; 17(8):e1009794. PubMed ID: 34437655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.